Recent advances in immune checkpoint inhibitors for non-small lung cancer treatment
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Recent advances in immune checkpoint inhibitors for non-small lung cancer treatment
Authors
Keywords
-
Journal
Frontiers in Oncology
Volume 12, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2022-09-27
DOI
10.3389/fonc.2022.1014156
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Understanding of Immune Escape Mechanisms and Advances in Cancer Immunotherapy
- (2022) Nasrin Aktar et al. Journal of Oncology
- Immune checkpoints and immunotherapy in non‑small cell lung cancer: Novel study progression, challenges and solutions (Review)
- (2021) Lin-Rui Ma et al. Oncology Letters
- Adverse events of immunotherapy in non-small cell lung cancer: A systematic review and network meta-analysis
- (2021) Chunyang Zhou et al. INTERNATIONAL IMMUNOPHARMACOLOGY
- A DNA-based nanocarrier for efficient cancer therapy
- (2020) Muhammad Abbas et al. Journal of Pharmaceutical Analysis
- Clinical Evaluation of Plasma Coagulation Parameters in Patients with Advanced‐stage Non‐small cell Lung Cancer Treated with Palliative Chemotherapy in China
- (2020) Muhammad Abbas et al. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
- Clinical Evaluation of Serum Tumor Markers in Patients With Advanced-Stage Non-Small Cell Lung Cancer Treated With Palliative Chemotherapy in China
- (2020) Muhammad Abbas et al. Frontiers in Oncology
- Immunotherapy Associated Pulmonary Toxicity: Biology Behind Clinical and Radiological Features
- (2019) Michele Porcu et al. Cancers
- Comparative effectiveness study of single high-dose cisplatin with fractionated doses cisplatin in first-line therapy for treatment-naive Chinese patients with advanced non–small-cell lung cancer
- (2019) Xiaoyou Li et al. CURRENT PROBLEMS IN CANCER
- Comparative Effectiveness of Pemetrexed-platinum Doublet Chemotherapy With or Without Bevacizumab as First-line Therapy for Treatment-naive Patients With Advanced Nonsquamous Non–small-cell Lung Cancer in China
- (2019) Xiaoyou Li et al. CLINICAL THERAPEUTICS
- Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial
- (2019) Howard West et al. LANCET ONCOLOGY
- First-line immune checkpoint blockade for advanced non-small-cell lung cancer: Travelling at the speed of light
- (2019) Christoph Jakob Ackermann et al. LUNG CANCER
- The dark side of immunotherapy: challenges facing the new hope in cancer treatment
- (2019) Eduard Teixidor et al. Annals of Translational Medicine
- Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC
- (2018) Mark A. Socinski et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer
- (2018) Leena Gandhi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Durvalumab: an investigational anti-PD-L1 monoclonal antibody for the treatment of urothelial carcinoma
- (2018) Izak Faiena et al. Drug Design Development and Therapy
- Immune-checkpoint inhibitor plus chemotherapy versus conventional chemotherapy for first-line treatment in advanced non-small cell lung carcinoma: a systematic review and meta-analysis
- (2018) Yixin Zhou et al. Journal for ImmunoTherapy of Cancer
- Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
- (2017) Achim Rittmeyer et al. LANCET
- Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis
- (2015) Anne Bertrand et al. BMC Medicine
- Global cancer statistics, 2012
- (2015) Lindsey A. Torre et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Safety and efficacy of MPDL3280A (anti-PDL1) in combination with bevacizumab (bev) and/or FOLFOX in patients (pts) with metastatic colorectal cancer (mCRC).
- (2015) Johanna C. Bendell et al. JOURNAL OF CLINICAL ONCOLOGY
- Antibodies to watch in 2016
- (2015) Janice M. Reichert mAbs
- Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
- (2015) Edward B. Garon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Development of PD-1/PD-L1 Pathway in Tumor Immune Microenvironment and Treatment for Non-Small Cell Lung Cancer
- (2015) Jiabei He et al. Scientific Reports
- EGFR and EGFRvIII analysis in glioblastoma as therapeutic biomarkers
- (2014) Claire Faulkner et al. BRITISH JOURNAL OF NEUROSURGERY
- Irradiation and anti–PD-L1 treatment synergistically promote antitumor immunity in mice
- (2014) Liufu Deng et al. JOURNAL OF CLINICAL INVESTIGATION
- Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab
- (2014) Suzanne L. Topalian et al. JOURNAL OF CLINICAL ONCOLOGY
- Combination Therapy with Anti–CTLA-4 and Anti–PD-1 Leads to Distinct Immunologic Changes In Vivo
- (2014) Rituparna Das et al. JOURNAL OF IMMUNOLOGY
- Ipilimumab in patients with cancer and the management of dermatologic adverse events
- (2014) Mario E. Lacouture et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Ceritinib in ALK-Rearranged Non–Small-Cell Lung Cancer
- (2014) Alice T. Shaw et al. NEW ENGLAND JOURNAL OF MEDICINE
- First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer
- (2014) Benjamin J. Solomon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pituitary Expression of CTLA-4 Mediates Hypophysitis Secondary to Administration of CTLA-4 Blocking Antibody
- (2014) S. Iwama et al. Science Translational Medicine
- Immune Cell-Poor Melanomas Benefit from PD-1 Blockade after Targeted Type I IFN Activation
- (2014) T. Bald et al. Cancer Discovery
- Immune checkpoint blockade immunotherapy to activate anti-tumour T-cell immunity
- (2013) Alan G. Ramsay BRITISH JOURNAL OF HAEMATOLOGY
- Antagonist Antibodies to PD-1 and B7-H1 (PD-L1) in the Treatment of Advanced Human Cancer
- (2013) M. Sznol et al. CLINICAL CANCER RESEARCH
- Adjuvant MAGE-A3 Immunotherapy in Resected Non–Small-Cell Lung Cancer: Phase II Randomized Study Results
- (2013) Johan Vansteenkiste et al. JOURNAL OF CLINICAL ONCOLOGY
- Impact of EGFR Inhibitor in Non–Small Cell Lung Cancer on Progression-Free and Overall Survival: A Meta-Analysis
- (2013) Chee Khoon Lee et al. JNCI-Journal of the National Cancer Institute
- Programmed death ligand-1 expression in non-small cell lung cancer
- (2013) Vamsidhar Velcheti et al. LABORATORY INVESTIGATION
- B7 family checkpoint regulators in immune regulation and disease
- (2013) Sabrina Ceeraz et al. TRENDS IN IMMUNOLOGY
- Tumor B7-H1 and B7-H3 Expression in Squamous Cell Carcinoma of the Lung
- (2012) Jennifer M. Boland et al. Clinical Lung Cancer
- Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting
- (2012) Hirokazu Matsushita et al. NATURE
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
- (2012) Julie R. Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape
- (2012) J. M. Taube et al. Science Translational Medicine
- Hallmarks of Cancer: The Next Generation
- (2011) Douglas Hanahan et al. CELL
- Ipilimumab
- (2011) Fiona Cameron et al. DRUGS
- Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
- (2011) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ipilimumab: its potential in non-small cell lung cancer
- (2011) Pascale Tomasini et al. Therapeutic Advances in Medical Oncology
- Programmed death-1 upregulation is correlated with dysfunction of tumor-infiltrating CD8+ T lymphocytes in human non-small cell lung cancer
- (2010) Yan Zhang et al. Cellular & Molecular Immunology
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors
- (2010) M. A. Curran et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- PD-1 signaling in primary T cells
- (2009) James L. Riley IMMUNOLOGICAL REVIEWS
- Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways
- (2008) Brian T. Fife et al. IMMUNOLOGICAL REVIEWS
- PI(3) kinase is associated with a mechanism of immunoresistance in breast and prostate cancer
- (2008) C A Crane et al. ONCOGENE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started